A comparison of Chinese and non-Chinese Canadian patients hospitalized with heart failure

BMC Cardiovascular Disorders

Jack V Tu²  Ching Lau²  Dennis T Ko²  Douglas S Lee⁴  Maria Chiu³  Baiju R Shah⁵  Gordon W Moe⁶  Laura C Maclagan³  Nicole K Van Dyke³  Darwin F Yeung¹ 

[1] Faculty of Medicine, University of Toronto, Toronto, Canada;Division of Cardiology, Schulich Heart Centre, Sunnybrook Health Sciences Centre, Toronto ON, Canada;Institute for Clinical Evaluative Sciences, 2075 Bayview Avenue G250, Toronto ON, Canada;Division of Cardiology, University Health Network, Toronto ON, Canada;Division of Endocrinology, Sunnybrook Health Sciences Centre, Toronto ON, Canada;St. Michael’s Hospital, Toronto, ON, Canada

关键词: Valvular heart disease;    Hypertension;    Heart failure;   

Others  :  855950
DOI  :  10.1186/1471-2261-13-114

 received in 2013-07-19, accepted in 2013-12-01,  发布年份 2013

【 摘 要 】

Background

Canadians of Chinese descent, represent one of the fastest growing visible minority groups in Canada, (as well as the second largest), but relatively little is known about the clinical features of heart failure (HF) in Chinese-Canadian versus non-Chinese Canadian patients.

Methods

We conducted a population-based analysis of urban patients hospitalized in Ontario, Canada for the first time with a most responsible diagnosis of HF between April 1, 1995 and March 31, 2008. Among the 99,278 patients, 1,339 (1.3%) were classified as Chinese using a previously validated list of Chinese surnames. Through linkage to other administrative databases, we compared the clinical characteristics, pharmacological management, and outcomes of Chinese versus non-Chinese HF patients.

Results

Ischemic heart disease was identified as the possible etiology of HF in a greater proportion of non-Chinese patients (47.7% vs. 35.3%; p < 0.001) whereas hypertension (26.1% vs. 16.1%; p < 0.001) and valvular heart disease (11.6% vs. 7.2%; p < 0.001) were relatively more common in Chinese patients. Chinese patients were prescribed angiotensin-converting enzyme (ACE) inhibitors less frequently (57.5% vs. 66.4%, p < 0.001) and angiotensin receptor blockers (ARBs) more frequently (17.4% vs. 8.9%, p < 0.001) compared to non-Chinese patients. They were also less likely to be adherent to ACE inhibitors over a 1-year follow up period. However, the 1-year case-fatality rates were comparable between the Chinese (31.7%) and non-Chinese (30.2%) subjects (p = 0.24).

Conclusion

There are important differences in the causes and medical management of HF in Chinese and non-Chinese patients residing in Canada. Despite these differences, the long-term outcomes of HF patients were similar.

【 授权许可】

   
2013 Yeung et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Moe GW, Tu J: Heart failure in the ethnic minorities. Curr Opin Cardiol 2010, 25:124-130.
• [2]Statistics Canada: 2006 Community profiles. http://www12.statcan.gc.ca/census-recensement/2006/dp-pd/prof/92-591/ webcite (Accessed January 11, 2013)
• [3]Tso DK, Moe G: Cardiovascular disease in Chinese Canadians: a case-mix study from an urban tertiary care cardiology clinic. Can J Cardiol 2002, 18:861-869.
• [4]Bahrami H, Kronmal R, Bluemke DA, et al.: Differences in the incidence of congestive heart failure by ethnicity: the multi-ethnic study of atherosclerosis. Arch Intern Med 2008, 168:2138-2145.
• [5]Kaul P, McAlister FA, Ezekowitz JA, Grover VK, Quan H: Ethnic differences in 1-year mortality among patients hospitalised with heart failure. Heart 2011, 97:1048-1053.
• [6]Jong P, Gong Y, Liu PP, Austin PC, Lee DS, Tu JV: Care and outcomes of patients newly hospitalized for heart failure in the community treated by cardiologists compared with other specialists. Circulation 2003, 108:184-191.
• [7]Shah BR, Chiu M, Amin S, Ramani M, Sadry S, Tu JV: Surname lists to identify South Asian and Chinese ethnicity from secondary data in Ontario, Canada: a validation study. BMC Med Res Methodol 2010, 10:42. BioMed Central Full Text
• [8]Charlson ME, Pompei P, Ales KL, MacKenzie CR: A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987, 40:373-383.
• [9]Deyo RA, Cherkin DC, Ciol MA: Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992, 45:613-619.
• [10]Quan H, Sundararajan V, Halfon P, et al.: Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005, 43:1130-1139.
• [11]Lee DS, Gona P, Vasan RS, et al.: Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction: insights from the Framingham heart study of the National Heart, Lung, and Blood Institute. Circulation 2009, 119:3070-3077.
• [12]Krumholz HM, Wang Y, Mattera JA, et al.: An administrative claims model suitable for profiling hospital performance based on 30-day mortality rates among patients with heart failure. Circulation 2006, 113:1693-1701.
• [13]Keenan PS, Normand SL, Lin Z, et al.: An administrative claims measure suitable for profiling hospital performance on the basis of 30-day all-cause readmission rates among patients with heart failure. Circ Cardiovasc Qual Outcomes 2008, 1:29-37.
• [14]Klatsky AL, Tekawa IS, Armstrong MA: Cardiovascular risk factors among Asian Americans. Public Health Rep 1996, 111(Suppl 2):62-64.
• [15]Sheth T, Nair C, Nargundkar M, Anand S, Yusuf S: Cardiovascular and cancer mortality among Canadians of European, south Asian and Chinese origin from 1979 to 1993: an analysis of 1.2 million deaths. CMAJ 1999, 161:132-138.
• [16]Mendez GF, Cowie MR: The epidemiological features of heart failure in developing countries: a review of the literature. Int J Cardiol 2001, 80:213-219.
• [17]Sanderson JE, Chan SK, Chan WW, Hung YT, Woo KS: The aetiology of heart failure in the Chinese population of Hong Kong–a prospective study of 730 consecutive patients. Int J Cardiol 1995, 51:29-35.
• [18]Bhatia RS, Tu JV, Lee DS, et al.: Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 2006, 355:260-269.
• [19]Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM: Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006, 355:251-259.
• [20]Yip GW, Ho PP, Woo KS, Sanderson JE: Comparison of frequencies of left ventricular systolic and diastolic heart failure in Chinese living in Hong Kong. Am J Cardiol 1999, 84:563-567.
• [21]Chan WK, Chan TY, Luk WK, Leung VK, Li TH, Critchley JA: A high incidence of cough in Chinese subjects treated with angiotensin converting enzyme inhibitors. Eur J Clin Pharmacol 1993, 44:299-300.
• [22]Woo KS, Nicholls MG: High prevalence of persistent cough with angiotensin converting enzyme inhibitors in Chinese. Br J Clin Pharmacol 1995, 40:141-144.
• [23]Ohkubo T, Chapman N, Neal B, et al.: Effects of an angiotensin-converting enzyme inhibitor-based regimen on pneumonia risk. Am J Respir Crit Care Med 2004, 169:1041-1045.